---
title: "Allogene Therapeutics publishes update to financial calendar"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303567553.md"
description: "Allogene Therapeutics announced updates to its financial calendar. The company will release third-quarter 2026 financial results on November 5 after market close, followed by a conference call at 2 p.m. PT. Additionally, a webinar on November 9 will review preliminary ALLO-329 Phase 1 data, and RESOLUTION study results will be presented at the ACR Convergence poster session on the same day."
datetime: "2026-10-29T12:32:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303567553.md)
  - [en](https://longbridge.com/en/news/303567553.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303567553.md)
generator: "portal-rs"
---

# Allogene Therapeutics publishes update to financial calendar

-   Allogene Therapeutics will release third-quarter 2026 financial results Nov. 5 after market close. \* A results conference call and business update will follow Nov. 5 at 2 p.m. PT/5 p.m. ET. \* A Nov. 9 webinar at 6 a.m. PT/9 a.m. ET will review preliminary ALLO-329 Phase 1 autoimmune safety and efficacy data. \* The initial RESOLUTION study results will also feature in an ACR Convergence poster presentation Nov. 9, 2026, 10:30 a.m.–12:30 p.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290830PRIMZONEFULLFEED9850845) on October 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)

## Related News & Research

- [Allogene's ALLO-329 improves skin scores in 8 of 10 scleroderma patients in Phase 1 trial](https://longbridge.com/en/news/304856012.md)
- [ALLO: ALLO-329 showed early SSc activity across LD approaches, including no lymphodepletion](https://longbridge.com/en/news/304856871.md)
- [Allogene Therapeutics (ALLO) Expected to Release Earnings on Thursday](https://longbridge.com/en/news/303544335.md)
- [Allogene Therapeutics Plans to Attend Three Investor Conferences](https://longbridge.com/en/news/303083684.md)
- [Allogene Highlights CAR T Clinical Progress in Kidney Cancer at SITC Meeting](https://longbridge.com/en/news/304117819.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**